A team of researchers led by the University of Adelaide, in collaboration with medical technology company Fertilis, has introduced a low-cost device to guide the only reproductive treatment available for men with low sperm counts. The first device of its kind will allow many IVF clinics to offer Intracytoplasmic Sperm Injection (ICSI) as a treatment, while a number of IVF procedures, such as embryonic culture, embryo cryopreservation and in vitro maturation, will also be developed using the device.ICSI is a slow and complex procedure that involves injecting one sperm into an egg to fertilize, and can only be performed by experienced embryologist.
New technologyimprove IVF success rates
This new technology – smaller than the size of a pin – holds up to 10 eggs in separated areas for immediate injection, making it easier for embryologists to track and avoid the risk of errors.Leading researcher Dr Kylie Dunning, of the University of Adelaide’s Robinson Research Institute, said the device would reduce treatment time by half, require less training for emerging physicians with less expensive equipment than current ICSI treatments and improve access to more patient procedures. ” is important for people who want to start a family that they can’t because of infertility, ”saidDr Dunning.
“By eliminating the need for a pipette that normally holds a fertilized egg in place during ICSI, this device simplifies the injection process, reduces dependence on a high level of technical experience and will significantly improve fetal production.”These findings remove significant barriers to the treatment of infertility and will enhance IVF success.” The device’s founder and founder of Fertilis, Professor Jeremy Thompson, said his company was excited to bring the equipment to market.”Where IVF science is successful, technology tends to falter – so far,” says Professor Thompson.
IVF
“ICSI has not changed since it was discovered 30 years ago. Innovative innovations in the IVF laboratory are the only way we can improve the success and reduce the financial and emotional burden on patients.” The machine will face global clinical trials by 2022.
This major development would not have been possible without the support of the Australian Research Council and the Hospital Research Foundation Group. Paul Flynn, Chief Executive Officer of the Hospital Research Foundation Group, said the organization was proud to support Dr Dunning’s research on time. three years ago to improve IVF success rates. “This program is designed to turn the game around for thousands of hopeful parents who need to rely on ICSI,” said Mr. Flynn. of Biomedicine at the University of Adelaide.
Source Journal Reference:Suliman H. Yagoub, Jeremy G. Thompson, Antony Orth, Kishan Dholakia, Brant C. Gibson, Kylie R. Dunning. Fabrication on the microscale: a two-photon polymerized device for oocyte microinjection. Journal of Assisted Reproduction and Genetics, 2022; DOI: 10.1007/s10815-022-02485-1
READ ALSO : Water method: Making H2O-enhanced electrical appliances
